Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Baxter
Accenture
Merck
Citi
Boehringer Ingelheim
Moodys
Farmers Insurance
Federal Trade Commission

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TICAGRELOR

« Back to Dashboard

Clinical Trials for Ticagrelor

Trial ID Title Status Sponsor Phase Summary
NCT00391872 A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome Completed AstraZeneca Phase 3 Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS.
NCT00528411 A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin Completed AstraZeneca Phase 2 The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of platelets. Blood clots prevent us from bleeding, but when they form inside the arteries their formation is linked to a risk of medical problems such as heart attack and stroke. This study investigated how long it takes for Ticagrelor to begin working and how long it takes for it to stop working after the last dose of drug. Ticagrelor will be compared to clopidogrel, an established anti-platelet treatment for preventing blood clots, and placebo plus Aspirin.
NCT00642811 A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders Completed AstraZeneca Phase 2 The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of platelets. Blood clots prevent us from bleeding, but when they form inside the arteries their formation is linked to a risk of medical problems such as heart attack and stroke. This study investigated the effect of Ticagrelor on inhibition of platelet aggregation compared with clopidogrel in patients previously identified as non-responsive to clopidogrel.
NCT01087723 European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial Completed The Medicines Company Phase 3 To show that the early administration of bivalirudin improves 30 day outcomes when compared to the current standard of care in participants with ST segment elevation acute coronary syndrome (STE-ACS), intended for a primary percutaneous coronary intervention (PCI) management strategy, presenting either via ambulance or to centers where PCI is not performed.
NCT01118325 An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease Completed AstraZeneca Phase 2 The purpose of the study is to determine the drug characteristics of Ticagrelor, and to determine if 4 weeks treatment will reduce the blood clotting.
NCT01225562 Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Completed AstraZeneca Phase 3 This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
NCT01226602 Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects. Completed AstraZeneca Phase 1 The purpose of this study is to determine if Ticagrelor increases the Adenosin induced coronary blood flow velocity.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ticagrelor

Condition Name

Condition Name for Ticagrelor
Intervention Trials
Coronary Artery Disease 66
Acute Coronary Syndrome 57
Myocardial Infarction 21
Healthy 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ticagrelor
Intervention Trials
Coronary Artery Disease 80
Coronary Disease 77
Acute Coronary Syndrome 77
Myocardial Ischemia 77
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ticagrelor

Trials by Country

Trials by Country for Ticagrelor
Location Trials
United States 528
Canada 82
China 56
Japan 55
Italy 46
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ticagrelor
Location Trials
Florida 38
New York 22
Texas 21
California 19
Maryland 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ticagrelor

Clinical Trial Phase

Clinical Trial Phase for Ticagrelor
Clinical Trial Phase Trials
Phase 4 162
Phase 3 49
Phase 2/Phase 3 9
[disabled in preview] 52
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ticagrelor
Clinical Trial Phase Trials
Recruiting 108
Completed 103
Not yet recruiting 35
[disabled in preview] 54
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ticagrelor

Sponsor Name

Sponsor Name for Ticagrelor
Sponsor Trials
AstraZeneca 79
University of Florida 15
University of Patras 12
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ticagrelor
Sponsor Trials
Other 333
Industry 111
U.S. Fed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Merck
Boehringer Ingelheim
Argus Health
Cipla
Federal Trade Commission
Teva
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.